Skip to content
    Novo Holdings logo

    Novo Holdings

    Hellerup, DenmarkFounded 1999
    novo.coLinkedIn
    Biotech & Life SciencesHealthcareFood & AgricultureManufacturingAIClimate & Energy

    Novo Holdings is a prominent life science investor that provides seed and venture capital to development-stage companies, focusing on innovative drugs, medical devices, and other technologies to improve patient care. They invest in biotechnology, medical technology, and digital health companies from an open evergreen fund, allowing for a long-term investment perspective.

    48% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (6 deals in the last 12 months vs 14 prior). Average disclosed round size is $114.3M (across 52 rounds with reported amounts).

    Find people at Novo Holdings on Goldilocks AI

    Portfolio

    56

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    6

    Team

    Morten Beck Jorgensen

    Morten Beck Jorgensen

    Managing Partner, Capital Investments

    AE

    Aleks Engel

    Partner

    JB

    Jeroen Bakker

    Partner, Seed Investments

    JT

    Jim Trenkle

    Partner in the Venture Investments Group

    JS

    Jørgen Søberg Petersen

    Partner

    KD

    Kartik Dharmadhikari

    Partner

    MK

    Max Klement

    Partner

    TG

    Thomas Grotkjær

    Partner, Planetary Health Investments

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    56 investments
    CompanyRoundAmountDate
    Chromologics logoChromologicsSeries A$7MNov 2025
    MATR Foods logoMATR FoodsSeries A$40MOct 2025
    Crystalys Therapeutics Inc. logoCrystalys Therapeutics Inc.Series A$205MSep 2025
    GlycoEra AG logoGlycoEra AGSeries B$130MMay 2025
    AgNext Technologies logoAgNext TechnologiesUnknown—Apr 2025
    AAugustine TherapeuticsSeries A$77.7MMar 2025
    WWindward BioSeries A$200MJan 2025
    Numab Therapeutics AG logoNumab Therapeutics AGSeries C$55MJan 2025
    Antag Therapeutics logoAntag TherapeuticsSeries A$80MDec 2024
    Adcendo ApS logoAdcendo ApSSeries B$135MNov 2024
    Quanta Dialysis Technologies logoQuanta Dialysis TechnologiesSeries E$60MNov 2024
    Elektrofi, Inc. logoElektrofi, Inc.Series C$112.3MOct 2024
    Booster Therapeutics logoBooster TherapeuticsSeed$15MOct 2024
    Qure.AI logoQure.AISeries D$65MSep 2024
    Qure.AI logoQure.AISeries D$65MSep 2024
    Route 92 Medical, Inc. logoRoute 92 Medical, Inc.Series F$50MSep 2024
    Magenta Medical logoMagenta MedicalGrowth$105MJul 2024
    RReunion Neuroscience Inc.Series A$103MMay 2024
    CIRCTEC logoCIRCTECGrowth$150MMay 2024
    Bluejay Therapeutics logoBluejay TherapeuticsSeries C$182MMay 2024
    Revagenix, Inc. logoRevagenix, Inc.Series B—Jan 2024
    OOnCusp TherapeuticsSeries A$100MJan 2024
    energyRe logoenergyReGrowth$1.2BDec 2023
    MapLight Therapeutics logoMapLight TherapeuticsSeries C$225MOct 2023
    Halodoc logoHalodocSeries D$100MAug 2023
    Page 1 of 3

    Top Co-Investors

    RA Capital Management8 shared
    DCVC Bio6 shared
    OrbiMed6 shared
    Sofinnova Partners5 shared
    Alexandria Venture Investments3 shared
    Pontifax3 shared
    Marshall Wace3 shared
    Janus Henderson Investors3 shared
    HealthCap3 shared
    Rock Springs Capital3 shared
    Merck Global Health Innovation Fund3 shared
    SR One3 shared
    Catalio Capital Management3 shared
    BlackRock2 shared
    Vivo Capital2 shared
    Avidity Partners2 shared
    Jeito Capital2 shared
    Forbion2 shared
    Atlas Venture2 shared
    Access Biotechnology2 shared

    Last updated: 13 March 2026